目的:研究异柠檬酸脱氢酶1(IDH1)突变对替莫唑胺化疗治疗脑胶质瘤患者的临床疗效及其对免疫细胞因子、预后的影响。方法:选取2021年10月至2022年10月苏州大学附属独墅湖医院手术切除且经病理证实的脑胶质瘤患者134例作为研究对象,直接...目的:研究异柠檬酸脱氢酶1(IDH1)突变对替莫唑胺化疗治疗脑胶质瘤患者的临床疗效及其对免疫细胞因子、预后的影响。方法:选取2021年10月至2022年10月苏州大学附属独墅湖医院手术切除且经病理证实的脑胶质瘤患者134例作为研究对象,直接测序法测定IDH1突变情况,免疫组化测定脑胶质瘤组织IDH1表达。脑胶质瘤患者均进行替莫唑胺化疗,分析IDH1突变对替莫唑胺化疗治疗脑胶质瘤临床疗效、免疫细胞因子(IFN-γ、IL-2、IL-4、IL-10)及预后生存状态的影响。结果:134例脑胶质瘤组织中79例存在IDH1突变,突变位点多为R132,突变率为58.96%,显著高于正常脑组织(χ^(2)=48.066,P<0.05)。免疫组化显示,134例脑胶质瘤组织中56例IDH1强阳性表达。IDH1突变型组WHO分级Ⅳ级占比低于IDHI野生型组[11.39%(9/79) vs 63.64%(35/55),Z=41.020,P<0.05],IDH1突变型组低分化比例高于IDHI野生型组[50.63%(40/79) vs 20.00%(11/55),χ^(2)=12.907,P<0.05]。IDH1突变型组总有效率高于IDH1野生型组[91.14%(72/79) vs 76.36%(42/55),χ^(2)=5.575,P<0.05]。IDH1突变型组IFN-γ、IL-2水平高于IDH1野生型组[(28.98±3.25) pg/ml vs (20.15±2.54) pg/ml、(33.42±4.25) pg/ml vs (25.23±3.52) pg/ml,t=16.870、11.750, P<0.05],IL-4、IL-10水平低于IDH1野生型组[(7.90±1.02) pg/ml vs(12.38±1.66) pg/ml、(8.79±1.00) pg/ml vs (15.26±1.23) pg/ml,t=19.330、33.500,P<0.05]。IDH1突变与替莫唑胺化疗后IFN-γ、IL-2水平呈正相关(r=0.845、0.772,P<0.05),与替莫唑胺化疗后IL-4、IL-10水平呈负相关(r=-0.786、-0.685,P<0.05)。IDH1突变型组替莫唑胺化疗后生存率高于IDH1野生型组[89.87%(71/79) vs 72.70%(40/55),Log Rank检验χ^(2)=5.208,P<0.05]。Cox回归分析发现,WHO分级Ⅲ级(RR=1.342)、低分化(RR=1.783)、IFN-γ(RR=1.808)、IL-2(RR=2.112)、IL-4(RR=2.342)、IL-10(RR=1.342)为危险因素,替莫唑胺化疗有效(RR=0.653)、IDH1突变(RR=0.895)为保护因素,影响脑胶质瘤患者替莫唑胺化疗预后(P<0.05)。结论:IDH1突变与脑胶质瘤患者疾病分级、分化程度有关,可影响替莫唑胺化疗疗效、免疫细胞因子表达,是替莫唑胺化疗后预后生存的保护因素。展开更多
Long noncoding RNA(lncRNA)IDH1 antisense RNA 1(IDH1-AS1)is involved in the progression of multiple cancers,but its role in epithelial ovarian cancer(EOC)is unknown.Therefore,we investigated the expression levels of ID...Long noncoding RNA(lncRNA)IDH1 antisense RNA 1(IDH1-AS1)is involved in the progression of multiple cancers,but its role in epithelial ovarian cancer(EOC)is unknown.Therefore,we investigated the expression levels of IDH1-AS1 in EOC cells and normal ovarian epithelial cells by quantitative real-time PCR(qPCR).We first evaluated the effects of IDH1-AS1 on the proliferation,migration,and invasion of EOC cells through cell counting kit-8,colony formation,EdU,transwell,wound-healing,and xenograft assays.We then explored the downstream targets of IDH1-AS1 and verified the results by a dual-luciferase reporter,qPCR,rescue experiments,and Western blotting.We found that the expression levels of IDH1-AS1 were lower in EOC cells than in normal ovarian epithelial cells.High IDH1-AS1 expression of EOC patients from the Gene Expression Profiling Interactive Analysis database indicated a favorable prognosis,because IDH1-AS1 inhibited cell proliferation and xenograft tumor growth of EOC.IDH1-AS1 sponged miR-518c-5p whose overexpression promoted EOC cell proliferation.The miR-518c-5p mimic also reversed the proliferation-inhibiting effect induced by IDH1-AS1 overexpression.Furthermore,we found that RNA binding motif protein 47(RBM47)was the downstream target of miR-518c-5p,that upregulation of RBM47 inhibited EOC cell proliferation,and that RBM47 overexpressing plasmid counteracted the proliferation-promoting effect caused by the IDH1-AS1 knockdown.Taken together,IDH1-AS1 may suppress EOC cell proliferation and tumor growth via the miR-518c-5p/RBM47 axis.展开更多
Background:The dysregulation of Isocitrate dehydrogenase(IDH)and the subsequent production of 2-Hydroxyglutrate(2HG)may alter the expression of epigenetic proteins in Grade 4 astrocytoma.The interplay mechanism betwee...Background:The dysregulation of Isocitrate dehydrogenase(IDH)and the subsequent production of 2-Hydroxyglutrate(2HG)may alter the expression of epigenetic proteins in Grade 4 astrocytoma.The interplay mechanism between IDH,O-6-methylguanine-DNA methyltransferase(MGMT)-promoter methylation,and protein methyltransferase proteins-5(PRMT5)activity,with tumor progression has never been described.Methods:A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors.Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis.Inter-cohort statistical significance was evaluated.Results:Both IDH-mutant WHO grade 4 astrocytomas(n=22,64.7%)and IDH-wildtype glioblastomas(n=12,35.3%)had upregulated PRMT5 gene expression except in one case.Out of the 22 IDH-mutant tumors,10(45.5%)tumors showed MGMT-promoter methylation and 12(54.5%)tumors had unmethylated MGMT.All IDH-wildtype tumors had unmethylated MGMT.There was a statistically significant relationship between MGMT-promoter methylation and IDH in G4 astrocytoma(p-value=0.006).Statistically significant differences in progression-free survival(PFS)were also observed among all G4 astrocytomas that expressed PRMT5 and received either temozolomide(TMZ)or TMZ plus other chemotherapies,regardless of their IDH or MGMT-methylation status(p-value=0.0014).Specifically,IDH-mutant tumors that had upregulated PRMT5 activity and MGMT-promoter methylation,who received only TMZ,have exhibited longer PFS.Conclusions:The relationship between PRMT5,MGMT-promoter,and IDH is not tridirectional.However,accumulation of D2-hydroxyglutarate(2-HG),which partially activates 2-OG-dependent deoxygenase,may not affect their activities.In IDH-wildtype glioblastomas,the 2HG-2OG pathway is typically inactive,leading to PRMT5 upregulation.TMZ alone,compared to TMZ-plus,can increase PFS in upregulated PRMT5 tumors.Thus,using a PRMT5 inhibitor in G4 astrocytomas may help in tumor regression.展开更多
文摘目的:研究异柠檬酸脱氢酶1(IDH1)突变对替莫唑胺化疗治疗脑胶质瘤患者的临床疗效及其对免疫细胞因子、预后的影响。方法:选取2021年10月至2022年10月苏州大学附属独墅湖医院手术切除且经病理证实的脑胶质瘤患者134例作为研究对象,直接测序法测定IDH1突变情况,免疫组化测定脑胶质瘤组织IDH1表达。脑胶质瘤患者均进行替莫唑胺化疗,分析IDH1突变对替莫唑胺化疗治疗脑胶质瘤临床疗效、免疫细胞因子(IFN-γ、IL-2、IL-4、IL-10)及预后生存状态的影响。结果:134例脑胶质瘤组织中79例存在IDH1突变,突变位点多为R132,突变率为58.96%,显著高于正常脑组织(χ^(2)=48.066,P<0.05)。免疫组化显示,134例脑胶质瘤组织中56例IDH1强阳性表达。IDH1突变型组WHO分级Ⅳ级占比低于IDHI野生型组[11.39%(9/79) vs 63.64%(35/55),Z=41.020,P<0.05],IDH1突变型组低分化比例高于IDHI野生型组[50.63%(40/79) vs 20.00%(11/55),χ^(2)=12.907,P<0.05]。IDH1突变型组总有效率高于IDH1野生型组[91.14%(72/79) vs 76.36%(42/55),χ^(2)=5.575,P<0.05]。IDH1突变型组IFN-γ、IL-2水平高于IDH1野生型组[(28.98±3.25) pg/ml vs (20.15±2.54) pg/ml、(33.42±4.25) pg/ml vs (25.23±3.52) pg/ml,t=16.870、11.750, P<0.05],IL-4、IL-10水平低于IDH1野生型组[(7.90±1.02) pg/ml vs(12.38±1.66) pg/ml、(8.79±1.00) pg/ml vs (15.26±1.23) pg/ml,t=19.330、33.500,P<0.05]。IDH1突变与替莫唑胺化疗后IFN-γ、IL-2水平呈正相关(r=0.845、0.772,P<0.05),与替莫唑胺化疗后IL-4、IL-10水平呈负相关(r=-0.786、-0.685,P<0.05)。IDH1突变型组替莫唑胺化疗后生存率高于IDH1野生型组[89.87%(71/79) vs 72.70%(40/55),Log Rank检验χ^(2)=5.208,P<0.05]。Cox回归分析发现,WHO分级Ⅲ级(RR=1.342)、低分化(RR=1.783)、IFN-γ(RR=1.808)、IL-2(RR=2.112)、IL-4(RR=2.342)、IL-10(RR=1.342)为危险因素,替莫唑胺化疗有效(RR=0.653)、IDH1突变(RR=0.895)为保护因素,影响脑胶质瘤患者替莫唑胺化疗预后(P<0.05)。结论:IDH1突变与脑胶质瘤患者疾病分级、分化程度有关,可影响替莫唑胺化疗疗效、免疫细胞因子表达,是替莫唑胺化疗后预后生存的保护因素。
基金supported by the National Natural Science Foundation of China(Grant Nos.81572556 and 81402139).
文摘Long noncoding RNA(lncRNA)IDH1 antisense RNA 1(IDH1-AS1)is involved in the progression of multiple cancers,but its role in epithelial ovarian cancer(EOC)is unknown.Therefore,we investigated the expression levels of IDH1-AS1 in EOC cells and normal ovarian epithelial cells by quantitative real-time PCR(qPCR).We first evaluated the effects of IDH1-AS1 on the proliferation,migration,and invasion of EOC cells through cell counting kit-8,colony formation,EdU,transwell,wound-healing,and xenograft assays.We then explored the downstream targets of IDH1-AS1 and verified the results by a dual-luciferase reporter,qPCR,rescue experiments,and Western blotting.We found that the expression levels of IDH1-AS1 were lower in EOC cells than in normal ovarian epithelial cells.High IDH1-AS1 expression of EOC patients from the Gene Expression Profiling Interactive Analysis database indicated a favorable prognosis,because IDH1-AS1 inhibited cell proliferation and xenograft tumor growth of EOC.IDH1-AS1 sponged miR-518c-5p whose overexpression promoted EOC cell proliferation.The miR-518c-5p mimic also reversed the proliferation-inhibiting effect induced by IDH1-AS1 overexpression.Furthermore,we found that RNA binding motif protein 47(RBM47)was the downstream target of miR-518c-5p,that upregulation of RBM47 inhibited EOC cell proliferation,and that RBM47 overexpressing plasmid counteracted the proliferation-promoting effect caused by the IDH1-AS1 knockdown.Taken together,IDH1-AS1 may suppress EOC cell proliferation and tumor growth via the miR-518c-5p/RBM47 axis.
文摘Background:The dysregulation of Isocitrate dehydrogenase(IDH)and the subsequent production of 2-Hydroxyglutrate(2HG)may alter the expression of epigenetic proteins in Grade 4 astrocytoma.The interplay mechanism between IDH,O-6-methylguanine-DNA methyltransferase(MGMT)-promoter methylation,and protein methyltransferase proteins-5(PRMT5)activity,with tumor progression has never been described.Methods:A retrospective cohort of 34 patients with G4 astrocytoma is classified into IDH-mutant and IDH-wildtype tumors.Both groups were tested for MGMT-promoter methylation and PRMT5 through methylation-specific and gene expression PCR analysis.Inter-cohort statistical significance was evaluated.Results:Both IDH-mutant WHO grade 4 astrocytomas(n=22,64.7%)and IDH-wildtype glioblastomas(n=12,35.3%)had upregulated PRMT5 gene expression except in one case.Out of the 22 IDH-mutant tumors,10(45.5%)tumors showed MGMT-promoter methylation and 12(54.5%)tumors had unmethylated MGMT.All IDH-wildtype tumors had unmethylated MGMT.There was a statistically significant relationship between MGMT-promoter methylation and IDH in G4 astrocytoma(p-value=0.006).Statistically significant differences in progression-free survival(PFS)were also observed among all G4 astrocytomas that expressed PRMT5 and received either temozolomide(TMZ)or TMZ plus other chemotherapies,regardless of their IDH or MGMT-methylation status(p-value=0.0014).Specifically,IDH-mutant tumors that had upregulated PRMT5 activity and MGMT-promoter methylation,who received only TMZ,have exhibited longer PFS.Conclusions:The relationship between PRMT5,MGMT-promoter,and IDH is not tridirectional.However,accumulation of D2-hydroxyglutarate(2-HG),which partially activates 2-OG-dependent deoxygenase,may not affect their activities.In IDH-wildtype glioblastomas,the 2HG-2OG pathway is typically inactive,leading to PRMT5 upregulation.TMZ alone,compared to TMZ-plus,can increase PFS in upregulated PRMT5 tumors.Thus,using a PRMT5 inhibitor in G4 astrocytomas may help in tumor regression.
